A US court just put ownership of CRISPR back in play

A major patent dispute over CRISPR gene-editing technology has once again divided the scientific community, with two key US researchers, Emmanuelle Charpentier and Emilia Doudna, appearing to secure recognition as the true inventors of their groundbreaking system after decades of legal contention. The conflict centers on who first developed the gene-editing tool used in treating genetic disorders like sickle cell disease, despite sharing the Nobel Prize for this work. A recent legal decision could cement their status as inventors by clarifying patent rights, highlighting ongoing debates about priority and ownership in biotechnology.